Estimates Revisions Madrigal Pharmaceuticals, Inc. Deutsche Boerse AG
Stocks
YDO1
US5588681057
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
09:27:36 01/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 446.65 EUR | +0.53% |
|
-0.78% | -9.85% |
| 24/09 | Analyst recommendations: Dropbox, Etsy, Meta Platforms, Okta, Rollins… |  |
| 23/09 | Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Madrigal Pharmaceuticals, Inc.(MDGL)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Madrigal Pharmaceuticals, Inc.(MDGL)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Madrigal Pharmaceuticals, Inc.(MDGL)
EBIT
Dividend / Share (DPS)
Data source:
Madrigal Pharmaceuticals, Inc.(MDGL)
Cash or Net Debt
- Stock Market
- Stocks
- MDGL Stock
- YDO1 Stock
- Consensus Madrigal Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
